ELISA Kit for Tumor Necrosis Factor Ligand Superfamily, Member 13 (TNFSF13)

CD256; APRIL; TALL2; TRDL1; ZTNF2; A Proliferation Inducing Ligand; TNF And APOL Related Leukocyte Expressed Ligand 2; TNF-Related Death Ligand 1

Specificity

This assay has high sensitivity and excellent specificity for detection of Tumor Necrosis Factor Ligand Superfamily, Member 13 (TNFSF13).
No significant cross-reactivity or interference between Tumor Necrosis Factor Ligand Superfamily, Member 13 (TNFSF13) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Tumor Necrosis Factor Ligand Superfamily, Member 13 (TNFSF13) and the recovery rates were calculated by comparing the measured value to the expected amount of Tumor Necrosis Factor Ligand Superfamily, Member 13 (TNFSF13) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 91-101 96
EDTA plasma(n=5) 98-105 101
heparin plasma(n=5) 80-105 80

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Tumor Necrosis Factor Ligand Superfamily, Member 13 (TNFSF13) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Tumor Necrosis Factor Ligand Superfamily, Member 13 (TNFSF13) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Tumor Necrosis Factor Ligand Superfamily, Member 13 (TNFSF13) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 98-105% 78-96% 89-102% 89-97%
EDTA plasma(n=5) 96-105% 89-101% 86-94% 96-103%
heparin plasma(n=5) 95-104% 82-98% 83-97% 82-102%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
TMB Substrate 1×9mL Stop Solution 1×6mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Journal of Critical Care Serum concentrations of A Proliferation-Inducing Ligand (APRIL) are elevated in sepsis and predict mortality in critically ill patients PubMed: 23337484
Haematologica Arrayed molecular barcoding identifies TNFSF13 as a positive regulator of acute myeloid leukemia-initiating cells Pubmed: 30819903
Gene A Significant Decrease of BAFF, APRIL, and BAFF Receptors Following Mesenchymal Stem Cell Transplantation in Patients with Refractory Rheumatoid Arthritis Pubmed: 31935514